Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775090 | 0.94 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL8775508 | 0.93 | TLR7 (0.86) | TLR7TLR8 | |
| SCHEMBL6127268 | 0.92 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL6127257 | 0.92 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL28693503 | 0.91 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL29349811 | 0.91 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL28693502 | 0.91 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL4206290 | 0.90 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL12343299 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL22523859 | 0.89 | TLR7 (0.80) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-07 | — | — | US | disclosed |
| EP-3949983-A1 | WATER SOLUBLE ADJUVANT | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-2012066336-A1 | BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | TLR7 12/4885TLR8 26/4885 |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | TLR7 12/4885TLR8 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.